Multiplicity in randomised trials I: endpoints and treatments.

Multiplicity problems emerge from investigators looking at many additional endpoints and treatment group comparisons. Thousands of potential comparisons can emanate from one trial. Investigators might only report the significant comparisons, an unscientific practice if unwitting, and fraudulent if i...

Descripción completa

Detalles Bibliográficos
Publicado en:Lancet Vol. 365; no. 9470; pp. 1591 - 1596
Autores principales: Schulz KF, Grimes DA, Schulz, Kenneth F, Grimes, David A
Formato: tables/charts Journal Article
Publicado: Lancet 4/30/2005
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106522861&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 106522861
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01406736
        LAN
      jtl: Lancet
      issn: 01406736
      maglogo: N
    pubinfo:
      dt: 4/30/2005
      vid: 365
      iid: 9470
      pid: 1297
      pub: Lancet
      place: Philadelphia, Pennsylvania
    artinfo:
      ui:
        106522861
        106522861
        NLM15866314
        2009031456
        10.1016/s0140-6736(05)66461-6
        NLM15866314
        106522861
      ppf: 1591
      ppct: 5
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Multiplicity in randomised trials I: endpoints and treatments.
      aug:
        au:
          Schulz KF
          Grimes DA
          Schulz, Kenneth F
          Grimes, David A
        affil: Family Health International, PO Box 13950, Research Triangle Park, NC 27709 USA
      sug:
        subj:
          Clinical Trials Methods
          Data Analysis, Statistical Methods
          Study Design
      ab: Multiplicity problems emerge from investigators looking at many additional endpoints and treatment group comparisons. Thousands of potential comparisons can emanate from one trial. Investigators might only report the significant comparisons, an unscientific practice if unwitting, and fraudulent if intentional. Researchers must report all the endpoints analysed and treatments compared. Some statisticians propose statistical adjustments to account for multiplicity. Simply defined, they test for no effects in all the primary endpoints undertaken versus an effect in one or more of those endpoints. In general, statistical adjustments for multiplicity provide crude answers to an irrelevant question. However, investigators should use adjustments when the clinical decision-making argument rests solely on one or more of the primary endpoints being significant. In these cases, adjustments somewhat rescue scattershot analyses. Readers need to be aware of the potential for under-reporting of analyses.
      pubtype: Academic Journal
      doctype:
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N